Home » News and press

NEWS AND PRESS

PRESS RELEASE: Reapplix confirms new funds raised

Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).

read more

Key patents granted in Europe and Eurasia

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in Europe and in Eurasia.

read more

Patent news – Patent granted in Japan

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.

read more

Reapplix Patents Granted in USA and Japan

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.

read more

PRESS RELEASE: Reapplix announces appointment of Graeme Brookes as new CEO

Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer. Graeme’s appointment significantly strengthens the commercial capabilities of the management team and provides increased emphasis on implementing this promising technology into clinical use.

read more
X